TR200002894T2 - L-Karnitin veya bir alkanoil L-Karnitin ve NADH ve/veya NADPH içeren kompozisyon - Google Patents

L-Karnitin veya bir alkanoil L-Karnitin ve NADH ve/veya NADPH içeren kompozisyon

Info

Publication number: TR200002894T2
Authority: TR; Turkey
Prior art keywords: carnitine; nadph; alkanoyl; composition containing; containing nadh
Prior art date: 1998-04-17

Application number

TR2000/02894T

Other languages

English (en)

Turkish (tr)

Inventor

Cavazza Claudio

Original Assignee

Sigma-Tau Healhscience S.P.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-17

Filing date

1999-04-14

Publication date

2001-01-22

1999-04-14 Application filed by Sigma-Tau Healhscience S.P.A. filed Critical Sigma-Tau Healhscience S.P.A.

2001-01-22 Publication of TR200002894T2 publication Critical patent/TR200002894T2/xx

Links

229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 title abstract 4
PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 title abstract 2
-1 alkanoyl L-Carnitine Chemical compound 0.000 title abstract 2
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 title abstract 2
ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 title 1
206010008874 Chronic Fatigue Syndrome Diseases 0.000 abstract 1
208000018737 Parkinson disease Diseases 0.000 abstract 1
XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 abstract 1
235000005911 diet Nutrition 0.000 abstract 1
230000000378 dietary effect Effects 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Obesity (AREA)
Diabetes (AREA)
Psychology (AREA)
Nutrition Science (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

TR2000/02894T 1998-04-17 1999-04-14 L-Karnitin veya bir alkanoil L-Karnitin ve NADH ve/veya NADPH içeren kompozisyon TR200002894T2 (tr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT98RM000238A IT1299161B1 (it)	1998-04-17	1998-04-17	Composizione comprendente l-carnitina o un'alcanoil l-carnitina e nadh e/o nadph

Publications (1)

Publication Number	Publication Date
TR200002894T2 true TR200002894T2 (tr)	2001-01-22

Family

ID=11405812

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TR2000/02894T TR200002894T2 (tr)	1998-04-17	1999-04-14	L-Karnitin veya bir alkanoil L-Karnitin ve NADH ve/veya NADPH içeren kompozisyon

Country Status (17)

Country	Link
EP (1)	EP1071424A1 (is)
JP (1)	JP2002512191A (is)
KR (1)	KR20010042765A (is)
CN (1)	CN1299283A (is)
AU (1)	AU750645B2 (is)
BR (1)	BR9909712A (is)
CA (1)	CA2328331A1 (is)
EE (1)	EE200000601A (is)
HU (1)	HUP0101914A3 (is)
IL (1)	IL139014A0 (is)
IS (1)	IS5663A (is)
IT (1)	IT1299161B1 (is)
NO (1)	NO20005128L (is)
PL (1)	PL343482A1 (is)
SK (1)	SK15442000A3 (is)
TR (1)	TR200002894T2 (is)
WO (1)	WO1999053921A1 (is)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8252309B2 (en)	2000-04-04	2012-08-28	Sigma-Tau Industrie Farmaceutiche Riunite Spa	Dietary supplement energy-providing to skeletal muscles
DE10326822A1 (de) *	2003-06-11	2005-01-05	Herzpharma Vita-Check Diagnosegeräte GmbH	Mittel zur Nahrungsergänzung, dieses Mittel enthaltende pharmazeutische Präparate und Verwendungen des Mittels
AU2007353211B2 (en) *	2007-05-11	2013-08-29	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.	Gel useful for the delivery of cosmetic active ingredients
WO2011022786A1 (en) *	2009-08-31	2011-03-03	Pharmaqest Pty Ltd	Methods for diagnosis and treatment of chronic fatigue syndrome
CN104306390A (zh) *	2014-10-23	2015-01-28	苏州人本药业有限公司	还原型辅酶ⅱ的用途
CN104840479A (zh) *	2015-02-17	2015-08-19	苏州人本药业有限公司	Nadph在制备治疗心脏疾病药物中的应用
US10894059B2 (en) *	2017-12-22	2021-01-19	Bontac Bio-Engineering (Shenzhen) Co., Ltd	NADH compound composition, and preparation and use thereof
EP3755160B1 (de)	2018-04-20	2021-11-03	Pacotrade AG	Vorrichtung zum zerkleinern von in blockform bereitgestellten tiefgefrorenen lebensmitteln
CN109170907A (zh) *	2018-08-30	2019-01-11	泓博元生命科技（深圳）有限公司	一种含有nmn的组合物、应用及运动饮料的制备方法
CN109105702A (zh) *	2018-08-30	2019-01-01	泓博元生命科技（深圳）有限公司	一种含有nadh的组合物、应用及能量补充剂的制备方法
JP7199518B2 (ja) *	2018-10-10	2023-01-05	蘇娥梁	補虚損用ヘルスケア製品組成物、その製造方法及び使用
CN117958433A (zh) *	2024-03-22	2024-05-03	四川新渔新美健康科技有限公司	不含咖啡因的抗疲劳功能组合物、饮料

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1054698A (is) *	1964-12-04
US5292538A (en) *	1992-07-22	1994-03-08	Metagenics, Inc.	Improved sustained energy and anabolic composition and method of making
DE4335454A1 (de) *	1993-10-19	1995-04-20	Schleicher Peter	Geriatrikum
JPH09110708A (ja) *	1995-08-11	1997-04-28	Taisho Pharmaceut Co Ltd	滋養強壮用生薬配合製剤
JPH0959161A (ja) *	1995-08-23	1997-03-04	Taisho Pharmaceut Co Ltd	疲労改善用組成物
IT1277953B1 (it) *	1995-12-21	1997-11-12	Sigma Tau Ind Farmaceuti	Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
IT1283951B1 (it) *	1996-03-15	1998-05-07	Mendes Srl	Uso della acetil l-carnitina o dei suoi sali farmacologicamente accettabili per il trattamento terapeutico o la profilassi di
US5712259A (en) *	1996-04-22	1998-01-27	Birkmayer Pharmaceuticals	NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
US6077828A (en) *	1996-04-25	2000-06-20	Abbott Laboratories	Method for the prevention and treatment of cachexia and anorexia
JPH10175856A (ja) *	1996-10-14	1998-06-30	Taisho Pharmaceut Co Ltd	疲労改善剤

1998
- 1998-04-17 IT IT98RM000238A patent/IT1299161B1/it active IP Right Grant
1999
- 1999-04-14 WO PCT/IT1999/000088 patent/WO1999053921A1/en not_active Ceased
- 1999-04-14 TR TR2000/02894T patent/TR200002894T2/xx unknown
- 1999-04-14 CA CA002328331A patent/CA2328331A1/en not_active Abandoned
- 1999-04-14 EP EP99916039A patent/EP1071424A1/en not_active Withdrawn
- 1999-04-14 AU AU34428/99A patent/AU750645B2/en not_active Ceased
- 1999-04-14 JP JP2000544325A patent/JP2002512191A/ja active Pending
- 1999-04-14 SK SK1544-2000A patent/SK15442000A3/sk unknown
- 1999-04-14 PL PL99343482A patent/PL343482A1/xx not_active Application Discontinuation
- 1999-04-14 HU HU0101914A patent/HUP0101914A3/hu unknown
- 1999-04-14 KR KR1020007011499A patent/KR20010042765A/ko not_active Withdrawn
- 1999-04-14 IL IL13901499A patent/IL139014A0/xx unknown
- 1999-04-14 BR BR9909712-5A patent/BR9909712A/pt not_active IP Right Cessation
- 1999-04-14 CN CN99805644A patent/CN1299283A/zh active Pending
- 1999-04-14 EE EEP200000601A patent/EE200000601A/xx unknown
2000
- 2000-10-12 NO NO20005128A patent/NO20005128L/no not_active Application Discontinuation
- 2000-10-13 IS IS5663A patent/IS5663A/is unknown

Also Published As

Publication number	Publication date
BR9909712A (pt)	2000-12-26
HUP0101914A2 (hu)	2002-03-28
ITRM980238A1 (it)	1999-10-17
IL139014A0 (en)	2001-11-25
IT1299161B1 (it)	2000-02-29
AU750645B2 (en)	2002-07-25
AU3442899A (en)	1999-11-08
SK15442000A3 (sk)	2001-06-11
CN1299283A (zh)	2001-06-13
PL343482A1 (en)	2001-08-27
NO20005128L (no)	2000-12-18
NO20005128D0 (no)	2000-10-12
HUP0101914A3 (en)	2002-12-28
IS5663A (is)	2000-10-13
EE200000601A (et)	2002-04-15
JP2002512191A (ja)	2002-04-23
CA2328331A1 (en)	1999-10-28
EP1071424A1 (en)	2001-01-31
WO1999053921A1 (en)	1999-10-28
KR20010042765A (ko)	2001-05-25
ITRM980238A0 (it)	1998-04-17

Similar Documents

Publication	Publication Date	Title
AR052921A1 (es)	2007-04-11	Uso de ranolazina para la preparacion de una composicion farmaceutica y composicion farmaceutica
TR200002894T2 (tr)	2001-01-22	L-Karnitin veya bir alkanoil L-Karnitin ve NADH ve/veya NADPH içeren kompozisyon
WO2003013549A3 (de)	2003-11-06	Formulierung enthaltend (lyso-) phosphatidylserin zur vorbeugung und behandlung von stresszuständen bei warmblütern
BR9710585A (pt)	2000-10-24	Composição para administração enteral, processo para melhorar a resistência fìsica ou desempenho atlético de um mamìfero, para aumentar a concentração de proteìna, massa corporal sem gordura ou massa muscular em um mamìfero, para diminuir a deposição de gordura corporal para uma dada ingestão calórica e aumentar a perda de gordura corporal em um mamìfero, para tratar os efeitos catabólicos de doença em um mamìfero, para aperfeiçoar a resistência fìsica ou o desempenho atléticode um mamìfero, e, para aumentar a massa de um corpo de carne magra de um mamìfero e diminuir a deposição de gordura
IL108285A0 (en)	1994-04-12	Use of riluzole for the treatment of parkinson's disease and parkinsonian syndromes
PT1163904E (pt)	2006-07-31	Composicao para a prevencao de doencas do musculo liso, compreendendo ascorbato, arginina e magnesio
PE20001325A1 (es)	2000-12-30	Combinacion de cerivastatina y fibratos
CA2377128A1 (en)	2001-02-01	Composition for the prevention of muscle fatigue and skeletal muscle adaptation to strenuous exercise
ATE366106T1 (de)	2007-07-15	Zusammensetzung für die pharmazeutische oder dietätische verwendung zur bekämpfung von haarausfall
HUP9700806A2 (hu)	1998-10-28	Tianeptin-nátriumsó nyújtott felszabadulását biztosító, szájon át beadható mátrix tabletta és eljárás előállítására
IT1295408B1 (it)	1999-05-12	Associazione di l-carnitina e alcanoil l-carnitine per il trattamento dell'alcoolismo
BRPI0409699A (pt)	2006-04-18	métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
MX9703810A (es)	1998-04-30	Medicamento que comprende un derivado de carnitinapara tratar la enfermedad de alzheimer en pacientes con inicio prematuro.
BR9813856A (pt)	2000-09-19	Processos para o tratamento de uma paciente que sofre de sìndrome pré-menstrual, depressão, anemia, enxaquecas ou distúrbios alimentares e para aumentar o nìvel de serotonin em um ser humano com nìvel reduzido do mesmo no fluxo sanguìneo e composição
ATE261733T1 (de)	2004-04-15	Zusammensetzung von ginseng und ginkgo zur verbesserung von kognitivem vermögen
BR0108261A (pt)	2003-03-05	Uso de mirtazapina, método de tratamento de um distúrbio do sono em um indivìduo, e, kit para paciente para o tratamento de distúrbios do sono
ES1052893U (es)	2003-03-01	Instrumento de gimnasia de balanceo.
CN2836786Y (zh)	2006-11-15	足底指压板
Burns et al.	2005	Acute Effects Of Whole-body Vibration And Bicycle Ergometry On Muscular Strength And Flexibility: 1344: Board# 199: 3: 30 PM-5: 00 PM
HUP9701606A2 (hu)	1998-06-29	Szulbutiamin alkalmazása bizonyos pszichomotoros és pszichointellektuális rendellenességek kezelésére használható gyógyszerkészítmények előállítására
Inoue et al.	2018	Increased Serum Irisin Level By Aerobic Training Is Involved In NO Production In Obese Rats: 2254 Board# 90 June 1 11: 00 AM-12: 30 PM
BR0303384A (pt)	2004-03-30	Citalopram e seus usos no tratamento de pressão sanguìnea elevada
Webster et al.	1989	The chief scientist reports... hyperbaric oxygen for multiple sclerosis patients
Johnson	2001	Ephedra and Ma Huang Consumption: Do the Benefits Outweigh the Risks?
Matheson	2001	Are We Losing the Injury-Prevention Battle?